EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieÄquivalenzstudieMultizentrische Studie

Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)

Vanita Noronha iD, Vijay Patil iD, Nandini Menon iD, Minit Shah iD, Vikas Ostwal iD, Anant Ramaswamy iD, Prabhat Bhargava iD, Srushti Shah, Kavita Nawale, Ankush Shetake, Vijayalakshmi Mathrudev, Laxman Sahu und 20 weitere

Journal of Clinical Oncology · 20.04.2026 · 44 (12) · 1083-1097

DOI: 10.1200/jco-25-01546 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2026. Verfasst von Vanita Noronha und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India. Hauptthemen laut MEDLINE: Nivolumab, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Immune checkpoint inhibitors (ICIs) achieve sufficient receptor occupancy at much lower than standard approved doses. We hypothesized that ultra-low-dose nivolumab would retain clinical efficacy. PATIENTS AND METHODS In this phase III randomized superiority trial, patients with advanced solid tumors (Eastern Cooperative Oncology Group 0-1) and progression on ≥1 prior line of systemic therapy were randomly assigned 1:1 to ultra-low-dose nivolumab (20 mg intravenously once every 2 weeks) or standard chemotherapy (docetaxel or paclitaxel, as per tumor type). Treatment continued until progression or intolerable toxicity. The primary end point was overall survival (OS). RESULTS From June 2020 to February 2024, we enrolled 500 patients: 250 per arm; 52% had head and neck and 36% lung cancers. The median number of prior lines of therapy was 1 (range, 1-8); 29% had received ≥2 prior lines. Median OS was significantly longer with ultra-low-dose nivolumab: 5.88 months (95% CI, 4.99 to 7.13) versus 4.70 months (95% CI, 3.91 to 5.65; hazard ratio [HR], 0.80 [95% CI, 0.66 to 0.97]; P = .022). One-year OS was 27.3% versus 16.9%. Median progression-free survival was similar: 2.04 months (95% CI, 2.00 to 2.10) with ultra-low-dose nivolumab and 2.09 months (95% CI, 2.04 to 2.17) with chemotherapy (HR, 1.03 [95% CI, 0.86 to 1.23]; P = .77). Grade ≥3 treatment-related adverse events were less frequent with ultra-low-dose nivolumab (42.5% v 60.8%; P < .001). Quality of life (QoL) was significantly better with ultra-low-dose nivolumab. CONCLUSION Ultra-low-dose nivolumab significantly improves OS versus chemotherapy in pretreated solid tumors, with fewer severe toxicities and better QoL. These findings support re-evaluation of ICI dosing strategies and may enhance global access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabNeoplasmsImmune Checkpoint InhibitorsHumansFemaleAgedMaleMiddle AgedAdultPaclitaxelNeoplasm Recurrence, LocalDocetaxelAged, 80 and over

Substanzen

NivolumabPaclitaxelImmune Checkpoint InhibitorsDocetaxel

Autor:innen und Institutionen

  • Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
  • Department of Medical Oncology, SunAct Cancer Institute and P D Hinduja Hospital, Mumbai, India.
  • Gunvati Jagan Nath Kapoor Foundation, Mumbai, India.
  • Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
  • Department of Nuclear Medicine, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
  • Department of Radiodiagnosis, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.

ORCID-Profile: Vanita Noronha, Vijay Patil, Nandini Menon, Minit Shah, Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava, Rajiv Kumar Kaushal, Nivedita Chakrabarty, Purvi Haria, Mehak Trikha, Sandeep Gedela, Shripad Banavali, Rajendra A Badwe, Kumar Prabhash

Zitieren

APA

Noronha, V., Patil, V., Menon, N., Shah, M., Ostwal, V., Ramaswamy, A., Bhargava, P., Shah, S., Nawale, K., Shetake, A., Mathrudev, V., Sahu, L., Mehta, S., Deshmukh, C., Gaikwad, S., Chavan, S., Narayan, R., Ingale, R., Dhumal, S., …, & Prabhash, K. (2026). Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). Journal of Clinical Oncology, 44(12), 1083-1097. https://doi.org/10.1200/jco-25-01546

Vancouver

Noronha V, Patil V, Menon N, Shah M, Ostwal V, Ramaswamy A, et al. Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). Journal of Clinical Oncology. 2026;44(12):1083-1097. doi:10.1200/jco-25-01546

BibTeX
@article{Noronha2026,
  author = {Noronha, Vanita and Patil, Vijay and Menon, Nandini and Shah, Minit and Ostwal, Vikas and Ramaswamy, Anant and Bhargava, Prabhat and Shah, Srushti and Nawale, Kavita and Shetake, Ankush and Mathrudev, Vijayalakshmi and Sahu, Laxman and Mehta, Shreya and Deshmukh, Charushila and Gaikwad, Savita and Chavan, Shital and Narayan, Ravi and Ingale, Ravi and Dhumal, Sachin and Kaushal, Rajiv Kumar and Pai, Trupti and Purandare, Nilendu and Janu, Amit and Chakrabarty, Nivedita and Sahu, Arpita and Haria, Purvi and Vaidyanathan, Arvind and Trikha, Mehak and Gedela, Sandeep and Banavali, Shripad and Badwe, Rajendra A and Prabhash, Kumar},
  title = {Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {12},
  pages = {1083--1097},
  doi = {10.1200/jco-25-01546}
}
Kostenlos starten →